DK0958371T3 - Cytopatiske vira til behandling og forebyggelse af neoplasi - Google Patents

Cytopatiske vira til behandling og forebyggelse af neoplasi

Info

Publication number
DK0958371T3
DK0958371T3 DK97951519T DK97951519T DK0958371T3 DK 0958371 T3 DK0958371 T3 DK 0958371T3 DK 97951519 T DK97951519 T DK 97951519T DK 97951519 T DK97951519 T DK 97951519T DK 0958371 T3 DK0958371 T3 DK 0958371T3
Authority
DK
Denmark
Prior art keywords
replication phenotype
cells
neoplastic cells
viral
neoplastic
Prior art date
Application number
DK97951519T
Other languages
English (en)
Inventor
James R Bischoff
Julie Nye
Ng Lelia
Sharon Horn
Angelica Williams
David Kirn
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of DK0958371T3 publication Critical patent/DK0958371T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK97951519T 1996-12-31 1997-12-10 Cytopatiske vira til behandling og forebyggelse af neoplasi DK0958371T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3461596P 1996-12-31 1996-12-31
PCT/US1997/022036 WO1998029555A2 (en) 1996-12-31 1997-12-10 Cytopathic viruses for therapy and prophylaxis of neoplasia

Publications (1)

Publication Number Publication Date
DK0958371T3 true DK0958371T3 (da) 2004-04-13

Family

ID=21877522

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97951519T DK0958371T3 (da) 1996-12-31 1997-12-10 Cytopatiske vira til behandling og forebyggelse af neoplasi

Country Status (11)

Country Link
US (1) US6080578A (da)
EP (1) EP0958371B1 (da)
JP (1) JP4225577B2 (da)
AT (1) ATE256195T1 (da)
AU (1) AU723604B2 (da)
CA (1) CA2273825C (da)
DE (1) DE69726759T2 (da)
DK (1) DK0958371T3 (da)
ES (1) ES2212815T3 (da)
PT (1) PT958371E (da)
WO (1) WO1998029555A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
JP2002515442A (ja) * 1998-05-15 2002-05-28 オニックス ファーマシューティカルズ，インコーポレイティド 癌を処置するためのアデノウィルス−化学治療剤のコンビネーション
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
JP2004505633A (ja) * 2000-08-03 2004-02-26 オニックス　ファーマシューティカルズ，インコーポレイティド アデノウイルスｅ１ｂ−５５ｋ単一アミノ酸変異体および使用方法
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
AU2002346084B2 (en) * 2001-07-23 2006-11-16 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
JP4354814B2 (ja) * 2001-09-29 2009-10-28 ヨンセイ ユニバーシティ 改善された疾患治療効果を有する組換えアデノウィルス及びそれを含む薬剤学的組成物
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2004042025A2 (en) 2002-11-01 2004-05-21 Cell Genesys, Inc. Cell-specific adenovirus vector comprising ebv-specific promoter
US20040202663A1 (en) * 2003-01-28 2004-10-14 Shanghai Sunway Biotech Co., Ltd. Therapy for primary and metastatic cancers
EP1646717A4 (en) * 2003-07-18 2006-12-20 Onyx Pharma Inc ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
EP2806883B1 (en) 2012-01-25 2019-04-24 DNAtrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
SG10201913795TA (en) 2012-02-02 2020-03-30 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
JP3556666B2 (ja) * 1993-02-16 2004-08-18 オニックス ファーマシューティカルズ，インコーポレイテイド 新形成の治療及び予防のための細胞障害ウイルス

Also Published As

Publication number Publication date
JP4225577B2 (ja) 2009-02-18
EP0958371A2 (en) 1999-11-24
DE69726759D1 (de) 2004-01-22
EP0958371B1 (en) 2003-12-10
AU5514598A (en) 1998-07-31
WO1998029555A2 (en) 1998-07-09
CA2273825C (en) 2011-02-08
DE69726759T2 (de) 2005-01-13
US6080578A (en) 2000-06-27
PT958371E (pt) 2004-04-30
AU723604B2 (en) 2000-08-31
JP2001508290A (ja) 2001-06-26
ES2212815T3 (es) 2004-08-01
WO1998029555A3 (en) 1998-10-01
CA2273825A1 (en) 1998-07-09
ATE256195T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
DK0689447T3 (da) Cytopatiske vira til behandling af og profylakse for neoplasia
DK0958371T3 (da) Cytopatiske vira til behandling og forebyggelse af neoplasi
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
WO1995032298A3 (en) Safe vectors for gene therapy
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HUP0400882A2 (hu) Onkolitikus vírusterápia
FI940054A0 (fi) Peptider av humant papillomavirus foer anvaendning i kompositioner som inducerar human T-cellsvar
NO922949L (no) Forbindelser og fremgangsmaater for inhibering av hiv- og beslektede virus
DE69133022D1 (de) Viral verursachte Zerstörung von Neoplastzellen
BG102106A (en) Phermaceutical composition containing proteinase inhibitor and monoglyceride
GR3035014T3 (en) N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors
MXPA02007271A (es) Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
DK0652957T3 (da) Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
MXPA02000969A (es) Vacuna de virus de inmuno-deficiencia humana atenuado controlado en forma condicional.
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
DE69730153D1 (de) EHV-1 Vektoren
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
Elliot-Lopez Treatment news: new options for the future
James T-20 and Trimeris
JPH02275819A (ja) エイズ原因ウィルスに対する抗ウィルス剤
UA9737A (uk) Спосіб відновлення прохідності стравоходу